Research ExplorerPublicationsGastric NET Subtypes: Do We Need An Additional One?

Gastric NET Subtypes: Do We Need An Additional One?

Standard

Gastric NET Subtypes: Do We Need An Additional One? / Lock, Guntram; Oelckers, Michael; Clauditz, Till Sebastian; Schrader, Jörg.

In: Z GASTROENTEROL, Vol. 59, No. 3, 03.2021, p. 255-258.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Lock, G, Oelckers, M, Clauditz, TS & Schrader, J 2021, 'Gastric NET Subtypes: Do We Need An Additional One?', Z GASTROENTEROL, vol. 59, no. 3, pp. 255-258. https://doi.org/10.1055/a-1348-2727

APA

Lock, G., Oelckers, M., Clauditz, T. S., & Schrader, J. (2021). Gastric NET Subtypes: Do We Need An Additional One? Z GASTROENTEROL, 59(3), 255-258. https://doi.org/10.1055/a-1348-2727

Vancouver

Lock G, Oelckers M, Clauditz TS, Schrader J. Gastric NET Subtypes: Do We Need An Additional One? Z GASTROENTEROL. 2021 Mar;59(3):255-258. https://doi.org/10.1055/a-1348-2727

Bibtex

@article{8ad0f8d8f9a94181a40ed586236b4ade,
title = "Gastric NET Subtypes: Do We Need An Additional One?",
abstract = "Depending on etiology, prognosis and malignant potential, recent S2k guideline differentiates gastric neuroendocrine tumors (gNET) in 4 types with different treatment implications.We report on a 55-year-old patient with the accidental finding of a 15 mm gNET. Apart from a prolonged use of proton pump inhibitors (PPI) for 20 years as a treatment for gastroesophageal reflux disease, there were no other associations or risk factors for gNETs. Formally, this patient would have been classified as a type III gNET, implicating gastric surgery. From a pathophysiological point of view, however, the assumed prolonged gastrin hypersecretion would have justified an assignment as a type I gNET. The gNET was resected by ESD, but histology showed an R1 situation. After cessation of PPIs, there is no recurrence so far. Besides, the initially documented numerous and large gland polyps showed an impressive regression only a few weeks after cessation of PPI.This case points to a probably underestimated gap in the present gNET classification. On the basis of present literature, the therapeutic dilemma of PPI-associated gNETs is discussed. A new assignment of PPI associated gNETs as type Ib could help to overcome this dilemma.",
author = "Guntram Lock and Michael Oelckers and Clauditz, {Till Sebastian} and J{\"o}rg Schrader",
note = "Thieme. All rights reserved.",
year = "2021",
month = mar,
doi = "10.1055/a-1348-2727",
language = "English",
volume = "59",
pages = "255--258",
journal = "Z GASTROENTEROL",
issn = "0044-2771",
publisher = "Karl Demeter Verlag GmbH",
number = "3",

}

RIS

TY - JOUR

T1 - Gastric NET Subtypes: Do We Need An Additional One?

AU - Lock, Guntram

AU - Oelckers, Michael

AU - Clauditz, Till Sebastian

AU - Schrader, Jörg

N1 - Thieme. All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - Depending on etiology, prognosis and malignant potential, recent S2k guideline differentiates gastric neuroendocrine tumors (gNET) in 4 types with different treatment implications.We report on a 55-year-old patient with the accidental finding of a 15 mm gNET. Apart from a prolonged use of proton pump inhibitors (PPI) for 20 years as a treatment for gastroesophageal reflux disease, there were no other associations or risk factors for gNETs. Formally, this patient would have been classified as a type III gNET, implicating gastric surgery. From a pathophysiological point of view, however, the assumed prolonged gastrin hypersecretion would have justified an assignment as a type I gNET. The gNET was resected by ESD, but histology showed an R1 situation. After cessation of PPIs, there is no recurrence so far. Besides, the initially documented numerous and large gland polyps showed an impressive regression only a few weeks after cessation of PPI.This case points to a probably underestimated gap in the present gNET classification. On the basis of present literature, the therapeutic dilemma of PPI-associated gNETs is discussed. A new assignment of PPI associated gNETs as type Ib could help to overcome this dilemma.

AB - Depending on etiology, prognosis and malignant potential, recent S2k guideline differentiates gastric neuroendocrine tumors (gNET) in 4 types with different treatment implications.We report on a 55-year-old patient with the accidental finding of a 15 mm gNET. Apart from a prolonged use of proton pump inhibitors (PPI) for 20 years as a treatment for gastroesophageal reflux disease, there were no other associations or risk factors for gNETs. Formally, this patient would have been classified as a type III gNET, implicating gastric surgery. From a pathophysiological point of view, however, the assumed prolonged gastrin hypersecretion would have justified an assignment as a type I gNET. The gNET was resected by ESD, but histology showed an R1 situation. After cessation of PPIs, there is no recurrence so far. Besides, the initially documented numerous and large gland polyps showed an impressive regression only a few weeks after cessation of PPI.This case points to a probably underestimated gap in the present gNET classification. On the basis of present literature, the therapeutic dilemma of PPI-associated gNETs is discussed. A new assignment of PPI associated gNETs as type Ib could help to overcome this dilemma.

U2 - 10.1055/a-1348-2727

DO - 10.1055/a-1348-2727

M3 - SCORING: Journal article

C2 - 33506449

VL - 59

SP - 255

EP - 258

JO - Z GASTROENTEROL

JF - Z GASTROENTEROL

SN - 0044-2771

IS - 3

ER -